Evidence map›Paper›PMID 29678145›Full record

ArticleBMC cancer2018

Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study).

H J F Brenkman, E C Gertsen, E Vegt, R van Hillegersberg, M I van Berge Henegouwen, S S Gisbertz, M D P Luyer, G A P Nieuwenhuijzen, J J B van Lanschot, S M Lagarde and 28 more

Registry-linked trialOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03208621 (Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03208621 unknown statusnot on this map

Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer: a Multicenter Prospective Study

Typeobservational_patient_registrySponsorUMC UtrechtRan2017 to 2025Enrolled394ConditionsGastric Cancer, Staging, FDG-PET/CT, Diagnostic Laparoscopy
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 1): AN UPDATE ON DIAGNOSIS, STAGING, ENDOSCOPIC TREATMENT AND FOLLOW-UP.Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery · 2020
    Guideline
  2. Article
  3. Impact ofAnnals of surgical oncology · 2024
    Article
  4. Article
  5. Prognostic Value of [Cancers · 2023
    Article
  6. Glucose metabolic profiles evaluated by PET associated with molecular characteristic landscape of gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Article
  7. Article
  8. Article
  9. Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Establishment of a [Journal of gastric cancer · 2020
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 15 institutions in 2 countries.

H J F BrenkmanDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
E C GertsenDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
E VegtThe Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
R van HillegersbergDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
M I van Berge HenegouwenAcademic Medical Center, Amsterdam, The Netherlands.
S S GisbertzAcademic Medical Center, Amsterdam, The Netherlands.
M D P LuyerCatharina Hospital, Eindhoven, The Netherlands.
G A P NieuwenhuijzenCatharina Hospital, Eindhoven, The Netherlands.
J J B van LanschotErasmus Medical Center, Rotterdam, The Netherlands.
S M LagardeErasmus Medical Center, Rotterdam, The Netherlands.
W O de SteurLeiden University Medical Center, Leiden, The Netherlands.
H H HartgrinkLeiden University Medical Center, Leiden, The Netherlands.
J H M B StootZuyderland Medical Center, Sittard-Geleen, The Netherlands.
K W E HulseweZuyderland Medical Center, Sittard-Geleen, The Netherlands.
E J Spillenaar BilgenRijnstate Hospital, Arnhem, The Netherlands.
M J van DetZGT Hospitals, Almelo, The Netherlands.
E A KouwenhovenZGT Hospitals, Almelo, The Netherlands.
D L van der PeetVU University Medical Center, Amsterdam, The Netherlands.
F DaamsVU University Medical Center, Amsterdam, The Netherlands.
J W van SandickThe Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands.
N C T van GriekenVU University Medical Center, Amsterdam, The Netherlands.
J HeisterkampElisabeth Twee-Steden Hospital, Tilburg, The Netherlands.
B van EttenUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J W HavemanUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J P PierieMedical Center Leeuwarden, Leeuwarden, The Netherlands.
F JonkerMedical Center Leeuwarden, Leeuwarden, The Netherlands.
A Y ThijssenAlbert Schweitzer Hospital, Dordrecht, The Netherlands.
E J T BeltAlbert Schweitzer Hospital, Dordrecht, The Netherlands.
P van DuijvendijkGelre Ziekenhuis, Apeldoorn, The Netherlands.
E WassenaarGelre Ziekenhuis, Apeldoorn, The Netherlands.
H W M van LaarhovenAcademic Medical Center, Amsterdam, The Netherlands.
F J WesselsDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
N Haj MohammadDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
H F van StelDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
G W J FrederixDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands.
P D SiersemaRadboud University Medical Center, Nijmegen, The Netherlands.
J P RuurdaDepartment of Surgery, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands. J.P.Ruurda@umcutrecht.nl.
PLASTIC Study Group
Utrecht University · NLRadboud University Nijmegen · NLGelre Hospitals · NLLeiden University Medical Center · NLUniversity Medical Center Groningen · NLZiekenhuis Groep Twente · NLMedisch Centrum Leeuwarden · NLZuyderland Medisch Centrum · NLAlbert Schweitzer Ziekenhuis · NLAmsterdam UMC Location University of Amsterdam · NLAmsterdam UMC Location Vrije Universiteit Amsterdam · NLElisabeth-TweeSteden Ziekenhuis · NLErasmus MC · NLNetherlands Cancer Institute-Antoni van Leeuwenhoek Hospital · NLThe Netherlands Cancer Institute · NL

Funding

ZonMw 843004103
6 · The paper itself

Abstract

backgroundInitial staging of gastric cancer consists of computed tomography (CT) and gastroscopy. In locally advanced (cT3-4) gastric cancer, fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT or PET) and staging laparoscopy (SL) may have a role in staging, but evidence is scarce. The aim of this study is to evaluate the impact and cost-effectiveness of PET and SL in addition to initial staging in patients with locally advanced gastric cancer.

methodsThis prospective observational cohort study will include all patients with a surgically resectable, advanced gastric adenocarcinoma (cT3-4b, N0-3, M0), that are scheduled for treatment with curative intent after initial staging with gastroscopy and CT. The modalities to be investigated in this study is the addition of PET and SL. The primary outcome of this study is the proportion of patients in whom the PET or SL lead to a change in treatment strategy. Secondary outcome parameters are: diagnostic performance, morbidity and mortality, quality of life, and cost-effectiveness of these additional diagnostic modalities. The study recently started in August 2017 with a duration of 36 months. At least 239 patients need to be included in this study to demonstrate that the diagnostic modalities are break-even. Based on the annual number of gastrectomies in the participating centers, it is estimated that approximately 543 patients are included in this study. DISCUSSION: In this study, it is hypothesized that performing PET and SL for locally advanced gastric adenocarcinomas results in a change of treatment strategy in 27% of patients and an annual cost-reduction in the Netherlands of €916.438 in this patient group by reducing futile treatment. The results of this study may be applicable to all countries with comparable treatment algorithms and health care systems.

trial registrationNCT03208621 . This trial was registered prospectively on June 30, 2017.

Indexed as

LaparoscopyNeoplasm StagingPositron-Emission TomographyAdenocarcinomaFemaleHumansMaleMultimodal ImagingProspective StudiesStomach NeoplasmsTomography, X-Ray ComputedWorkflowGastrectomyGastric cancerLaparoscopy

Identifiers

PMID29678145
PMCPMC5910577
OpenAlexW2800812695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.